| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10018630 | HBV | ENSG00000178445.10 | protein_coding | GLDC | No | No | 2731 | P23378 |
| TVIS10042366 | HBV | ENSG00000178445.10 | protein_coding | GLDC | No | No | 2731 | P23378 |
| TVIS20039651 | HPV | ENSG00000178445.10 | protein_coding | GLDC | No | No | 2731 | P23378 |
| TVIS20046483 | HPV | ENSG00000178445.10 | protein_coding | GLDC | No | No | 2731 | P23378 |
| TVIS20067124 | HPV | ENSG00000178445.10 | protein_coding | GLDC | No | No | 2731 | P23378 |
| TVIS20045991 | HPV | ENSG00000178445.10 | protein_coding | GLDC | No | No | 2731 | P23378 |
| TVIS44028234 | HTLV-1 | ENSG00000178445.10 | protein_coding | GLDC | No | No | 2731 | P23378 |
| TVIS44013282 | HTLV-1 | ENSG00000178445.10 | protein_coding | GLDC | No | No | 2731 | P23378 |
| TVIS44046150 | HTLV-1 | ENSG00000178445.10 | protein_coding | GLDC | No | No | 2731 | P23378 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | GLDC |
|---|---|
| DrugBank ID | DB00114 |
| Drug Name | Pyridoxal phosphate |
| Target ID | BE0000618 |
| UniProt ID | P23378 |
| Regulation Type | cofactor |
| PubMed IDs | 15791207; 16228305 |
| Citations | Nakai T, Nakagawa N, Maoka N, Masui R, Kuramitsu S, Kamiya N: Structure of P-protein of the glycine cleavage system: implications for nonketotic hyperglycinemia. EMBO J. 2005 Apr 20;24(8):1523-36. Epub 2005 Mar 24.@@Igamberdiev AU, Ivlev AA, Bykova NV, Threlkeld CN, Lea PJ, Gardestrom P: Decarboxylation of glycine contributes to carbon isotope fractionation in photosynthetic organisms. Photosynth Res. 2001;67(3):177-84. |
| Groups | Approved; Investigational; Nutraceutical |
| Direct Classification | Pyridoxals and derivatives |
| SMILES | CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O |
| Pathways | Histidinemia; 3-Methylglutaconic Aciduria Type I; Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency); beta-Ketothiolase Deficiency; Tyrosine Metabolism; Disulfiram Action Pathway; Hyperprolinemia Type II; Glutamate Metabolism; Argininosuccinic Aciduria; Tyrosinemia Type I; Hyperinsulinism-Hyperammonemia Syndrome; Porphyrin Metabolism; 2-Methyl-3-hydroxybutryl-CoA Dehydrogenase Deficiency; Glutaric Aciduria Type I; Propanoate Metabolism; Taurine and Hypotaurine Metabolism; Catecholamine Biosynthesis; Glycine and Serine Metabolism; Carnitine Synthesis; Tyrosinemia Type 3 (TYRO3); Selenoamino Acid Metabolism; Carbamoyl Phosphate Synthetase Deficiency; Hyperprolinemia Type I; Saccharopinuria/Hyperlysinemia II; Histidine Metabolism; Cystathionine beta-Synthase Deficiency; Arginine and Proline Metabolism; Starch and Sucrose Metabolism; Globoid Cell Leukodystrophy; Ammonia Recycling |
| PharmGKB | PA164749650 |
| ChEMBL | CHEMBL82202 |
